Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $12.96 Consensus Price Target from Brokerages

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have received an average recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $12.9550.

VYGR has been the subject of a number of analyst reports. Weiss Ratings restated a “sell (d)” rating on shares of Voyager Therapeutics in a research note on Wednesday, October 8th. Wedbush reduced their target price on shares of Voyager Therapeutics from $9.00 to $8.00 and set an “outperform” rating for the company in a report on Thursday, August 7th. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Voyager Therapeutics in a report on Monday, September 15th.

Voyager Therapeutics Trading Up 0.2%

Shares of NASDAQ VYGR opened at $4.23 on Friday. Voyager Therapeutics has a 12-month low of $2.64 and a 12-month high of $7.44. The stock’s fifty day simple moving average is $4.51 and its two-hundred day simple moving average is $3.71. The stock has a market capitalization of $234.64 million, a PE ratio of -2.29 and a beta of 0.95.

Insider Buying and Selling

In related news, CFO Nathan D. Jorgensen sold 7,666 shares of the stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $4.78, for a total transaction of $36,643.48. Following the completion of the sale, the chief financial officer owned 123,834 shares of the company’s stock, valued at $591,926.52. This represents a 5.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 4.53% of the stock is owned by insiders.

Hedge Funds Weigh In On Voyager Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of VYGR. AQR Capital Management LLC lifted its holdings in shares of Voyager Therapeutics by 179.3% during the 1st quarter. AQR Capital Management LLC now owns 495,260 shares of the company’s stock valued at $1,674,000 after purchasing an additional 317,927 shares during the last quarter. Acadian Asset Management LLC grew its stake in Voyager Therapeutics by 863.3% during the 1st quarter. Acadian Asset Management LLC now owns 230,708 shares of the company’s stock worth $778,000 after buying an additional 206,758 shares during the last quarter. Nuveen LLC acquired a new position in Voyager Therapeutics during the 1st quarter valued at about $368,000. Hsbc Holdings PLC raised its stake in Voyager Therapeutics by 118.5% in the second quarter. Hsbc Holdings PLC now owns 148,377 shares of the company’s stock valued at $440,000 after buying an additional 80,474 shares during the last quarter. Finally, Strs Ohio purchased a new stake in Voyager Therapeutics in the first quarter valued at about $256,000. 48.03% of the stock is owned by hedge funds and other institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.